DBV Technologies S.A. (DBVT)

DBV Technologies S.A. (DBVT) Healthcare & Pipeline Overview

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing epicutaneous immunotherapy products, with Viaskin Peanut as its lead candidate for treating peanut allergies. The company also has ongoing research in milk and egg allergies, positioning it as a key player in the food allergy treatment space.

What Is the Investment Thesis for DBVT?

DBV Technologies presents a notable research candidate within the biotechnology sector, primarily driven by its innovative epicutaneous immunotherapy platform. The successful completion of Phase III trials for Viaskin Peanut represents a significant milestone, potentially paving the way for regulatory approval and commercialization. The company's focus on addressing food allergies, a growing global health concern, positions it favorably in a market with substantial unmet needs. Key value drivers include the potential FDA approval of Viaskin Peanut, expansion of the Viaskin platform to other food allergies like milk and egg, and strategic partnerships for commercialization and product development. However, investors may want to evaluate potential risks such as regulatory hurdles, clinical trial outcomes for other pipeline products, and competition from alternative allergy treatments. With a market cap of $371.11M and a beta of -0.20, DBV Technologies offers a unique risk-reward profile for investors seeking exposure to the biopharmaceutical industry.

Based on FMP financials and quantitative analysis

DBVT Key Highlights

• Viaskin Peanut has completed Phase III clinical trials for peanut allergies, demonstrating potential for market approval.
• DBV Technologies is developing Viaskin Milk, currently in Phase I/II clinical trials for cow's milk protein allergy (CMPA), expanding its product pipeline.
• The company has a collaboration with Nestlé Health Science to develop MAG1C, a diagnostic tool for non-IgE mediated CMPA.
• DBV Technologies' epicutaneous immunotherapy (EPIT) platform offers a potentially safer and more convenient alternative to traditional oral immunotherapy.
• The company's research programs include a vaccine for respiratory syncytial virus (RSV) and treatments for Crohn's disease, celiac disease, and type I diabetes, indicating long-term growth potential.

Who Are DBVT's Competitors?

DBVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DBVT's Key Strengths?

• Innovative epicutaneous immunotherapy (EPIT) platform.
• Viaskin Peanut has completed Phase III clinical trials.
• Collaboration with Nestlé Health Science.
• Focus on a growing market with unmet needs.

What Are DBVT's Weaknesses?

• Clinical-stage company with no approved products.
• Reliance on the success of Viaskin Peanut.
• Limited financial resources.
• Negative beta, suggesting potential underperformance in a strong market.

What Could Drive DBVT Stock Higher?

• Potential FDA approval of Viaskin Peanut for peanut allergies.
• Clinical trial results for Viaskin Milk in cow's milk protein allergy (CMPA).
• Expansion of the Viaskin platform to other food allergies.
• Strategic partnerships for commercialization and product development.

What Are the Key Risks for DBVT?

• Financial-distress signal — its Altman Z-Score of 0.31 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles and delays in product approval.
• Competition from alternative allergy treatments.
• Clinical trial failures for other pipeline products.
• Patent expiration and generic competition.
• Currency risk associated with investing in an ADR.

What Are the Growth Opportunities for DBVT?

• Expansion of Viaskin Platform: DBV Technologies has the opportunity to expand its Viaskin platform to address a wider range of food allergies beyond peanut, milk, and egg. This includes targeting allergies to tree nuts, shellfish, and other common allergens. The market for these additional food allergy treatments is substantial, offering significant revenue potential. Successful development and commercialization of new Viaskin products could solidify DBV Technologies' position as a leader in the food allergy space. Timeline: Ongoing, with potential product launches in the next 3-5 years.
• Strategic Partnerships: DBV Technologies can leverage strategic partnerships with pharmaceutical companies, healthcare providers, and patient advocacy groups to expand its market reach and accelerate commercialization efforts. Collaborations with established players in the healthcare industry can provide access to distribution networks, marketing expertise, and regulatory support. These partnerships can also facilitate the development of combination therapies and diagnostic tools. Timeline: Ongoing, with potential partnership announcements in the next 1-2 years.
• Geographic Expansion: DBV Technologies has the opportunity to expand its geographic presence beyond Europe and North America. Emerging markets in Asia, Latin America, and Africa are experiencing a growing prevalence of food allergies, creating significant demand for effective treatments. Entering these markets requires navigating local regulatory requirements and establishing distribution channels. Timeline: 3-5 years, contingent on regulatory approvals and market access strategies.
• Development of Diagnostic Tools: DBV Technologies can develop and commercialize diagnostic tools for food allergies, complementing its therapeutic products. The MAG1C atopy patch test for cow's milk protein allergy (CMPA) represents a successful example of this strategy. Expanding the diagnostic portfolio to include tests for other food allergies can provide a comprehensive solution for patients and healthcare providers. Timeline: Ongoing, with potential product launches in the next 2-3 years.
• New Therapeutic Areas: DBV Technologies can leverage its epicutaneous immunotherapy platform to develop treatments for other immune-mediated diseases beyond food allergies. This includes exploring applications in autoimmune disorders, inflammatory conditions, and infectious diseases. Expanding into new therapeutic areas can diversify the company's product pipeline and reduce its reliance on the food allergy market. Timeline: Long-term, with potential clinical trials in the next 5-7 years.

What Opportunities Does DBVT Have?

• Expansion of Viaskin platform to other food allergies.
• Strategic partnerships for commercialization and product development.
• Geographic expansion into emerging markets.
• Development of diagnostic tools for food allergies.

What Threats Does DBVT Face?

• Regulatory hurdles and potential delays in product approval.
• Competition from alternative allergy treatments.
• Clinical trial failures for other pipeline products.
• Patent expiration and generic competition.

What Are DBVT's Competitive Advantages?

• Proprietary epicutaneous immunotherapy (EPIT) platform.
• Viaskin technology offers a potentially safer and more convenient alternative to traditional oral immunotherapy.
• Strong intellectual property portfolio protecting its products and technologies.
• Collaboration with Nestlé Health Science provides access to diagnostic tools and market reach.

What Does DBVT Do?

DBV Technologies S.A., founded in 2002 and headquartered in Montrouge, France, is a clinical-stage biopharmaceutical company dedicated to the research and development of epicutaneous immunotherapy (EPIT) products. The company's core technology, Viaskin, aims to deliver allergenic proteins to the immune system through intact skin, offering a potentially safer and more convenient alternative to traditional oral immunotherapy. Their lead product candidate, Viaskin Peanut, has completed Phase III clinical trials for the treatment of peanut allergies in children aged 4 to 11 years, adolescents, and adults. This innovative approach seeks to desensitize patients to peanut allergens, reducing the risk of allergic reactions upon accidental exposure. Beyond peanut allergies, DBV Technologies is also developing Viaskin Milk, currently in Phase I/II clinical trials for cow's milk protein allergy (CMPA), and Viaskin Egg, a pre-clinical stage product targeting hen's egg allergy. The company's pipeline extends to earlier-stage research programs, including a vaccine for respiratory syncytial virus (RSV) and treatments for Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to develop MAG1C, an atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers, further diversifying their product offerings and market reach.

What Products and Services Does DBVT Offer?

• Develop epicutaneous immunotherapy (EPIT) products.
• Research and develop treatments for food allergies.
• Focus on peanut, milk, and egg allergies.
• Utilize the Viaskin platform to deliver allergenic proteins through the skin.
• Conduct clinical trials to evaluate the safety and efficacy of its products.
• Collaborate with Nestlé Health Science to develop diagnostic tools.
• Explore treatments for other immune-mediated diseases.

How Does DBVT Make Money?

• Develop and commercialize epicutaneous immunotherapy products.
• Generate revenue through product sales and licensing agreements.
• Collaborate with strategic partners for product development and commercialization.
• Focus on the food allergy market with potential expansion into other therapeutic areas.

What Industry Does DBVT Operate In?

DBV Technologies operates within the biotechnology industry, specifically targeting the food allergy market. This market is characterized by a growing prevalence of food allergies worldwide, driving demand for innovative diagnostic and therapeutic solutions. The competitive landscape includes companies developing oral immunotherapies, biologics, and other novel treatments for food allergies. DBV Technologies' epicutaneous immunotherapy platform differentiates it from competitors by offering a potentially safer and more convenient route of administration. The global food allergy market is projected to reach billions of dollars in the coming years, presenting significant growth opportunities for companies like DBV Technologies.

Who Are DBVT's Key Customers?

• Patients with food allergies, particularly peanut, milk, and egg allergies.
• Parents of children with food allergies.
• Allergists and other healthcare providers.
• Hospitals and clinics.

DBV Technologies S.A. (DBVT) Valuation Context

Valued at $371.11M, DBVT is classified as a small-cap stock. Relative to its peer group, DBVT's quantitative score of 43/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -63.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -28.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.76 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

DBV Technologies S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.31 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project DBV Technologies S.A. revenue of about $4.4M for fiscal 2026, with EPS near $-0.95. The estimate reflects 3 contributing analysts.

DBVT Financials

DBVT Latest News

DBVT Analyst Consensus

DBVT MoonshotScore

Common Questions About DBVT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources